Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW679769 plus ondansetron for prevention of postoperative and post-discharge nausea and vomiting in high-risk women undergoing laparoscopic or laparotomic surgery
2004-000369-37Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vercirnon in postoperative nausea and vomiting (PONV) (3 arms), sponsored by GSK. Primary endpoint: Complete response during first 72 hours after emergence from anesthesia. Started Dec 2004; status: completed.
02
Drugs
vercirnon
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2004-000369-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000369-37.